Amendment to Option and License Agreement between Alpine Immune Sciences Inc. and AbbVie Global Enterprises Ltd.

Contract Categories: Business Finance › Modification Agreements
Summary

Alpine Immune Sciences Inc. and AbbVie Global Enterprises Ltd. have agreed to amend their existing Option and License Agreement, originally dated June 17, 2017. This amendment replaces Schedule 1.157 of the original agreement with a new version attached as Exhibit A. The amendment becomes effective once both parties sign the letter. The document does not disclose the specific contents of the new schedule due to confidentiality.

Read More Arrow
EX-10.2 3 alpn-ex102_20220630.htm EX-10.2 Document
CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE DESIGNATED AS [***].


April 12, 2022

Alpine Immune Sciences Inc.
188 E Blaine St Suite 200
Seattle, WA 98102
United States
Attention: Paul Rickey, CFO
Re:    The Option and License Agreement between Alpine Immune Sciences Inc. (“Alpine”) and AbbVie Global Enterprises Ltd. (as assignee of AbbVie Ireland Unlimited Company) (“AbbVie”), made and entered into as of June 17, 2017 (the “Agreement”)
To Whom it May Concern:
This letter serves to memorialize the agreement between AbbVie and Alpine to replace Schedule 1.157 of the Agreement with the Schedule 1.157 attached to this letter as Exhibit A.
Please countersign this letter below and return a copy to AbbVie. This letter will be effective upon execution by each of the parties. If you have any questions regarding this letter, please contact John Larson, Senior Director, Alliance Management, at [***].
Sincerely,
/s/ Arthur C. Price    
AbbVie Global Enterprises Ltd.
Name: Arthur C. Price
Title: Director
Agreed:
/s/ Paul Rickey    
Alpine Immune Sciences Inc.
Name: Paul Rickey
Title: CFO





Exhibit A
Schedule 1.157
[***] Success Completion Criteria

[***]